行情

ALDX

ALDX

Aldeyra
NASDAQ

实时行情|Nasdaq Last Sale

11.24
+0.01
+0.09%
交易中 13:40 06/24 EDT
开盘
11.25
昨收
11.23
最高
11.35
最低
11.13
成交量
59.70万
成交额
--
52周最高
15.95
52周最低
3.950
市值
6.48亿
市盈率(TTM)
-10.9787
分时
5日
1月
3月
1年
5年
过去一周的知名内幕人士购买:安费诺,Aldeyra,狼人治疗药等
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Once again, some insiders have taken advantage of initial public offerings. A couple of chief executive officers were among the insiders ...
Benzinga · 05/08 16:10
Aldeyra Therapeutics(ALDX)收到Alliance Global Partners的收购
Alliance Global Partners analyst Matthew Cross maintained a Buy rating on Aldeyra Therapeutics (ALDX) today and set a price target of $32.00. The
SmarterAnalyst · 05/07 17:25
Aldeyra Therapeutics(ALDX)连续第三次购买
After Leerink Partners and Oppenheimer gave Aldeyra Therapeutics (NASDAQ: ALDX) a Buy rating last month, the company received another Buy, this time from
SmarterAnalyst · 05/07 10:37
Aldeyra Therapeutics(ALDX)获得HC Wainwright的买入评级
In a report released today, Edwin Zhang from H.C. Wainwright reiterated a Buy rating on Aldeyra Therapeutics (ALDX), with a price target of $26.00. The
SmarterAnalyst · 05/06 16:55
JonesTrading重申对Aldeyra Therapeutics(ALDX)的买入评级
JonesTrading analyst Prakhar Agrawal reiterated a Buy rating on Aldeyra Therapeutics (ALDX) today. The company's shares closed last Thursday at $11.92.
SmarterAnalyst · 05/06 15:55
Aldeyra Therapeutics Q1每股盈余(0.25)超出预期(0.27)
Aldeyra Therapeutics (NASDAQ:ALDX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 26.47 percent increase over losses of $(0.34) per share
Benzinga · 05/06 11:59
每日生物技术脉动:默克公司的Keytruda获得美国食品和药物管理局(FDA)的另一项批准,Moderna减免了收入损失,Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5)
Benzinga · 05/06 11:49
Brief-Aldeyra Therapeutics报告第一季度每股亏损0.25美元
reuters.com · 05/06 11:28
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解ALDX最新的财务预测,通过ALDX每股收益,每股净资产,每股现金流等数据分析Aldeyra近期的经营情况,然后做出明智的投资选择。
分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测ALDX价格均价为25.67,最高价位32.00,最低价为16.00。
EPS
机构持股
总机构数: 152
机构持股: 3,422.52万
持股比例: 59.39%
总股本: 5,763.12万
类型机构数股数
增持
30
887.65万
建仓
33
518.41万
减持
24
298.46万
平仓
21
173.36万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.26%
制药与医学研究
+1.19%
高管信息
Chairman/Independent Director
Richard Douglas
President/Chief Executive Officer/Director
Todd Brady
Chief Financial Officer
Joshua Reed
Other
Stephen Machatha
Senior Vice President
James Gow
Independent Director
Ben Bronstein
Independent Director
Martin Joyce
Independent Director
Nancy Miller-rich
Independent Director
Gary Phillips
Independent Director
Neal Walker
暂无数据
ALDX 简况
Aldeyra Therapeutics, Inc.(原名:Aldexa Therapeutics, Inc.)是一家生物技术公司。该公司主要活动包括筹集资金及研发活动。该公司从事鉴定和开发高醛相关疾病的治疗产品。该公司专注于开发用于治疗炎症引起的疾病以及天然病毒或称为醛类的炎性化学物质引起的先天性代谢紊乱的治疗产品。该公司已经开发各种用于隔离和允许醛类降解的醛阱小分子。该公司正在开发的醛阱NS2是一种用于治疗过敏性结膜炎和相关罕见过敏性眼部疾病、非感染性前葡萄膜炎、舍格伦-拉松综合征(SLS)和琥珀酸半醛脱氢酶缺乏症的候选产品。

微牛提供Aldeyra Therapeutics Inc(NASDAQ-ALDX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ALDX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ALDX股票基本功能。